Biotech | August 24, 2021
Pfizer to acquire Trillium Therapeutics
Trillium’s portfolio includes biologics that are designed to enhance the ability of patients’ innate immune system to detect and destroy cancer cells
Trillium’s portfolio includes biologics that are designed to enhance the ability of patients’ innate immune system to detect and destroy cancer cells
The approval allows it to market its products in the country
Preclinical and early human data indicate BriLife may confer enhanced immunity against Delta variant
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
The research underscores growing concern that the intersection of neurodevelopmental conditions and social disadvantage can significantly compound health risks across the life course
Researchers emphasized that the benefit persisted well beyond the treatment period, reinforcing the clinical rationale for time-limited therapy in selected patients
Country’s deep scientific talent pool and its growing role as a clinical trial destination makes it central to how Parexel serves sponsors
M&A activity, IPOs and late-stage investments gain momentum as investors prioritize clinical validation, while early-stage biotech firms continue to face funding challenges
New Tracxn report highlights growing investor confidence in automated cell therapy production, with Cellares and Ori Biotech dominating funding and regulatory milestones
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
